Research Analysts Offer Predictions for CRDF Q1 Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Cardiff Oncology in a note issued to investors on Thursday, February 27th. William Blair analyst A. Hsieh expects that the company will post earnings per share of ($0.26) for the quarter. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. William Blair also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.28) EPS.

Several other research analysts have also commented on CRDF. Piper Sandler lifted their price target on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. HC Wainwright boosted their target price on Cardiff Oncology from $13.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, February 28th.

Cardiff Oncology Stock Down 2.4 %

Shares of Cardiff Oncology stock opened at $3.73 on Monday. The firm has a market cap of $190.73 million, a price-to-earnings ratio of -3.97 and a beta of 1.77. The business has a 50-day moving average price of $4.05 and a 200-day moving average price of $3.26. Cardiff Oncology has a twelve month low of $2.01 and a twelve month high of $6.42.

Institutional Trading of Cardiff Oncology

A number of institutional investors have recently modified their holdings of CRDF. BNP Paribas Financial Markets purchased a new position in shares of Cardiff Oncology in the fourth quarter worth $25,000. ProShare Advisors LLC acquired a new position in shares of Cardiff Oncology in the 4th quarter valued at about $50,000. Raymond James Financial Inc. purchased a new stake in shares of Cardiff Oncology in the fourth quarter worth about $56,000. Voya Investment Management LLC purchased a new stake in Cardiff Oncology in the 4th quarter worth approximately $57,000. Finally, Caxton Corp acquired a new position in shares of Cardiff Oncology in the 4th quarter valued at $58,000. 16.29% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Gary W. Pace bought 350,115 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were acquired at an average price of $2.60 per share, with a total value of $910,299.00. Following the transaction, the director now owns 1,047,876 shares of the company’s stock, valued at $2,724,477.60. The trade was a 50.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 7.80% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.